Future research directions should prioritize targeting KLF4 to reprogram TAMs from a tumor‐promoting M2 phenotype to a tumor‐suppressing M1 phenotype, which could pave the way for novel cancer treatments [130]. This evidence concerns the gene KLF4 and neoplasm.